CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 304 enrolled
Drug / intervention
Placebo +4 moredrug
Likely dose
PF-04937319 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01517373
NCT01517373Phase 2Completed
CompareCT.gov

A Phase 2, Randomized, Double-blinded, Placebo-controlled, Dose-ranging, Parallel Group Study To Evaluate Safety And Efficacy Of Pf-04937319 And Glimepiride In Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin

Pfizer·interventional·Posted Jan 25, 2012·Updated Jan 31, 2017

In Brief

A Phase 2 clinical trial evaluating Placebo, PF-04937319 10 mg, and 3 other interventions for Diabetes Mellitus, Type 2. Completed, enrolled 304 participants across 53 sites in 7 countries.

Detailed Summary

This is a study to understand efficacy and safety of investigational agent (PF-04937319) compared to approved agent (glimepiride) in patients with diabetes on metformin

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesBulgaria, Canada, Hungary, India, Slovakia, Taiwan, United States
Collaborators--

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJan 25, 2012
Enrollment StartFeb 1, 2012
Primary CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 14.4 years ago

Interventions

Placebodrug

Combination of tablets and capsules, a total of 3 pills/dose, administered once daily for 84-days

PF-04937319 10 mgdrug

Combination of tablets and capsules, dose of 10 mg, a total of 3 pills/dose, administered once daily for 84-days

PF-04937319 50 mgdrug

Combination of tablets and capsules, dose of 50 mg, a total of 3 pills/dose, administered once daily for 84-days

PF-04937319 100 mgdrug

Combination of tablets and capsules, dose of 100 mg, a total of 3 pills/dose, administered once daily for 84-days

Glimepiridedrug

Combination of tablets and capsules, dose of up to 6 mg, a total of 3 pills/dose, administered once daily for 84-days